Androgen deprivation therapy (ADT) is the backbone of systemic therapy for advanced prostate cancer,1,2 and novel hormonal therapies (androgen receptor inhibitors [ARIs]), such as darolutamide, enzalutamide, or apalutamide, are among the most frequently used life-prolonging therapies.3 However, these hormonal therapies are associated with adverse events, including effects on patients’ physical and cognitive functioning. This evidence concerns the gene AR and Familial prostate cancer.